BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

CADL upcoming catalysts

Candel Therapeutics, Inc.: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 0 FDA event(s). Subscribe to CADL (.ics).

Drugs: aglatimagene besadenovec, valacyclovir

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-02 est.P2Candel Therapeutics, Inc. CADLNCT07332000 A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecProstate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma)recruiting45

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-12 est.P2Candel Therapeutics, Inc. CADLNCT02446093 Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinomaunknown54

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.